Cancer Startup Allogene Makes Trading Debut As Largest Biotech To IPO Since 2009

Please make sure your browser supports JavaScript and cookies and that you are not blocking them from loading. For more information you can review our Terms of Service and Cookie Policy.

Source : https://www.bloomberg.com/news/articles/2018-10-11/allogene-makes-trading-debut-as-largest-biotech-to-ipo-since-09

Cancer Startup Allogene Makes Trading Debut as Largest Biotech to IPO Since 2009
Cancer Treater’s IPO Nets $102M; Device Maker Reduces Plans
U.S. IPO Recap: 11 Deals Prince In Busiest Week Since November 2007, 8 Companies Set Terms
Bain Capital teams with Pfizer to create new neuroscience-focused company
4 Disruptive Healthcare Stocks You've Never Heard Of
The Guide to Surging Biotech ETFs
Boom: 2018's biotech IPOs
Cancer Startup Allogene Makes Trading Debut as Largest Biotech to IPO Since 2009
Dow 30 Stock Roundup: Pfizer Gains, Crimea, Biotech Stocks Drag Markets
Top VC deals: Baidu invests in electric vehicles, Gilead buys cancer-fighting start-up